US FDA approves Revolution Medicines' pancreatic cancer drug
26/08/2026 15:43
US FDA approves Revolution Medicines' pancreatic cancer drug Aug 26 (Reuters) - The U.S. Food and Drug Administration approved Revolution Medicines' RVMD.O targeted drug for metastatic pancreatic cancer, the regulator said on Wednesday.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath)
Recent news on Revolution Medicines
See all newsRevolution's Rasonque improves survival across subgroups in pancreatic cancer patients
Analysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug